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Background: Diabetes and vitamin D deficiency are global epidemics. Researchers have long been exploring the
role of potentially modifiable factors to manage type 2 diabetes. We conducted a systematic review of prospective
studies and randomized controlled trials that involved vitamin D supplementation and specifically intended to
study glycemic outcomes related to type 2 diabetes.
Methods: Two authors independently searched Medline and PubMed for longitudinal studies that had assessed
the effect of vitamin D supplements on glycemic control, insulin resistance and beta-cell dysfunction in patients
with diabetes.
Results: Seventeen randomized control trials and seven longitudinal studies with a minimum follow-up of one
month were included.
Results of the various short-term studies (follow up ≤ 3 months) suggested that vitamin D supplementation had a
positive impact on glycemic control and metabolic parameters such as insulin resistance and beta cell dysfunction.
However, the evidence was weak due to the low methodological quality of the studies. There was no significant
effect on HbA1c, beta cell function and insulin resistance in the long-term studies (follow up > 3 months). There
existed heterogeneity in the methodology of the studies, inclusion criteria, mode of supplementation of vitamin D
and the duration of follow up.
Conclusions: Current evidence based on randomized controlled trials and longitudinal studies do not support the
notion that vitamin D supplementation can improve hyperglycemia, beta cell secretion or insulin sensitivity in
patients with type 2 diabetes. Large-scale trials with proper study design, optimal vitamin D supplementation and
longer follow up need to be conducted.
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Diabetes is now widely prevalent globally [1]. Presently,
around 285 million people have diabetes and this num-
ber is expected to reach 438 million by the year 2030
[2]. More alarmingly, many people are developing type 2
diabetes early in their lives. Achieving excellent glycemic
control is crucial in the management of diabetes as well
as preventing the onset of serious and life threatening
complications of diabetes [3,4]. Despite the advances in* Correspondence: nishanigil.haroon@utoronto.ca
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normoglycemia or optimal glycemic control is still con-
sidered challenging [5]. This is because care of type 2
diabetes warrants intense life-style adaptations, poly-
pharmacy and insulin centered regimens. Conventional
oral anti-diabetic medications are associated with hypo-
glycemias. Besides, insulin treatment has been linked to
poor compliance, weight gain and possibly adverse car-
diovascular outcomes. In addition, progressive beta-cell
dysfunction and insulin resistance can make anti-
diabetic agents less effective [6]. Despite large-scaleentral. This is an Open Access article distributed under the terms of the Creative
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treatment adherence is only around 60% [7]. Moreover,
newer anti-diabetic drugs such as incretin analogs and
ultra short acting insulin analogs are expensive and
hence many patients in the developing world where
type 2 diabetes is prevalent cannot afford these medica-
tions. Besides, the long-term safety of the newer agents
is still being explored. Also, no complete cure has yet
been discovered for 2 diabetes.
Given the existence of many such challenges in the
management if diabetes, researchers have been explor-
ing the role of modifiable factors to manage type 2 dia-
betes. Vitamin D insufficiency and deficiency are being
increasingly recognized world-wide [8]. Serum 25 (OH)
D levels have even been linked to mortality in the gen-
eral population [9]. Vitamin D level in plasma has been
linked to the occurrence of metabolic syndrome and
insulin resistance [10]. Though epidemiological studies
demonstrate an association between low serum 25(OH)
vitamin D and glucose intolerance, intervention trials
using vitamin D have produced mixed results [11,12].
Epidemiological data also suggest a possible link be-
tween low vitamin D and diabetic complications such
as nephropathy, neuropathy and retinopathy [11].
Recent observational data reports a beneficial effect of
vitamin D on preventing the onset of diabetes [13]. But
the potential benefits of vitamin D supplementation on
glycemic control are still debated. A meta-analysis in
2012 that included longitudinal studies and randomized
controlled trials (RCTs) reported a small improvement
on fasting glucose and insulin resistance but no benefi-
cial effect was seen on HbA1c [14]. However, studies
included in this meta-analysis were heterogeneous in
terms of the study subjects as healthy subjects, and those
with impaired fasting glucose or type 2 diabetes were in-
cluded. Clearly long-term studies were lacking. Further,
the dose of supplemental vitamin D and duration of
follow-up varied widely across the studies. The number
of eligible studies was also small and data on HbA1C, a
better marker of glycemic status was available only from
four studies. Moreover, many studies did not analyze the
effect of all possible confounders. In addition, more
studies have been published in the two years since this
review [11,15-23]. So it is important to update available
evidence in this regard.Aims
Thus we conducted a systematic review of prospective
studies and randomized controlled trials that assessed
the role of vitamin D supplementation on glycemic
outcomes related to type 2 diabetes. The purpose of
our review is to synopsize the present knowledge on
this topic.Materials and methods
Selection criteria
Inclusion criteria
We considered studies that assessed the effect of vitamin
D supplementation on glycemic control with a minimum
follow-up period of one month as eligible. Studies had to
have more than seventy percent of subjects with type 2
diabetes and be published as a full-text original article.
The search was restricted to human studies published in
English language. No restrictions were applied regarding
geography or gender of the subjects. Eligible studies had
to have reported at least one of the following primary
outcomes of interest: insulin sensitivity and insulin se-
cretion by homeostasis model assessment (HOMA-IR
(insulin resistance) or B (beta-cell function)) and/or
hemoglobin A1c (HbA1c).
Exclusion criteria
Review articles, studies done in children and adoles-
cents, studies with lack of longitudinal follow-up, case
reports, editorials and studies with follow-up less than
1 month were excluded. We also excluded studies that
did not include any therapeutic intervention with vita-
min D and studies in which subjects had gestational dia-
betes, post partum diabetes, diabetic nephropathy, type
1 diabetes and prediabetes. Studies that assessed incident
diabetes as the primary outcome and studies in which
patients had no diabetes were also excluded. If there
were more than one publication from the same group
and had similar interventions, the study with the max-
imum duration of follow-up and number of subjects was
included [22].
We used the Preferred Reporting Items for Systematic
Reviews and Meta-analyses statement to guide the
reporting of this systematic review [24].
Search strategy
Two authors conducted the literature search independ-
ently. Systematic searches of MEDLINE and EMBASE
were conducted from inception to July 31, 2014. The
main aim was to identify randomized controlled trials
that assessed the effect of vitamin D supplementation on
glycemic control in patients with type 2 diabetes. The
search strategy is outlined in Figure 1.
The search strategy used diabetes and vitamin D re-
lated search terms with glycemic control related search
terms using a Boolean operator “AND”. The keywords
and Medical Subject Headings were: ((“vitamin D” OR
“cholecalciferol” OR “vitamin D3” OR “vitamin D2” OR
“calcitriol” OR “ergocalciferol” OR “one-alpha-hydroxy-
cholecalciferol” OR “doxercalciferol” OR “alphacalcidol”
OR “alfacalcidol”) AND (“diabetes” OR “T2DM” OR
“hyperglycemia” OR “hyperglycaemia” OR “dysglycemia”
OR “diabetes mellitus” OR “diabetic”) AND (“glycemic
Figure 1 Flow chart for identifying eligible studies.
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“insulin sensitivity” OR “beta cell function” OR “euglyce-
mia” OR “insulin resistance” OR “insulin” OR “HOMA”
OR “fasting glucose” OR “FBS” OR “post prandial” OR
“insulin secretion” OR “interventional” OR “insulin sen-
sitivity” OR “glucose” OR “glucose homeostasis” OR
“glycaemic control” OR “glucose tolerance” OR “effects”
OR “changes”)) NOT ((“pregnancy” OR “gestational” OR
“gestational diabetes”) OR (“associations” OR “associ-
ation”) OR (“type-1 diabetes” OR “T1DM” OR “type 1
diabetes” OR “diabetes type 1” OR “children” OR “ado-
lescents”) OR (“pre diabetes” OR “pre-diabetes” OR
“prediabetes”) OR (“meta-analysis”) OR (“polycystic”)
OR (“healthy” OR “nondiabetic”)).
We screened the reference lists of the eligible primary
studies, narrative and systematic reviews so as to identify
other candidate studies. Two authors independently
assessed all retrieved records on titles and abstracts. Dis-
agreements were resolved by discussion. If required, a
third independent author was consulted to reach con-
sensus. We aligned our final choice on the assessment of
the full-text articles by two independent authors. A
study was included if the earlier described inclusion cri-
teria were fulfilled. Two authors independently extracted
data from the selected studies. Data on study character-
istics such as the number of patients, study design,
country of origin, mean age, and use of vitamin D, and
were collected whenever available. Information on base-
line HbA1c, 25-OH-vitamin D levels, and homeostasis
model assessment index of beta cell function (HOMA-
B) and insulin resistance (HOMA-IR) and longitudinal
change in all these parameters were also extracted when-
ever possible. HOMA-B and HOMA-IR are able to pro-
vide estimates of steady state beta cell function and
insulin sensitivity and these are derived as percentages
of a normal reference population. Studies with more
than 3 months of follow-up were considered as long-term studies and those with a follow-up of three months
or less were considered as short-term studies.
Quality assessment
We used the Newcastle–Ottawa Scale to address the qual-
ity of the eligible studies and the Jadad scale to assess the
quality of the RCTs [25,26]. The Newcastle–Ottawa Scale
employs a star scoring system to judge the study aspects
including comparability, selection of groups, and assess-
ment of the outcome of interest. The quality of the defin-
ition of selection groups is graded from 0–4, comparability
from 0–2 and ascertainment of exposures and outcomes
from 0–3. Higher points indicate that the study has good
quality. Two authors conducted the quality assessment
independently and disagreements were discussed until a
consensus was reached.
Results
The search strategy is shown in Figure 1. Studies with
more than 3 months of follow-up were considered as
long-term studies and those with a follow-up of three
months or less were considered as short-term studies.
Sixteen studies were short-term studies. The remaining
studies were long –term studies with follow up ranging
from sixteen weeks to 18 months. There were two publi-
cations from the same research group based in Iran and
hence the study with the maximum duration of follow-
up, compete data and maximum number of subjects
were included [22]. We identified twenty-four studies
including 17 RCTs and 7 longitudinal studies as eligible
based on the pre-defined inclusion –exclusion criteria
[11,15-23,27-41]. Half of the studies were (13/24) con-
ducted in Caucasians.
Clinical and biochemical characteristics of the short-term
studies
There were 16 short term-studies and 13 amongst them
were randomized controlled trials. Data are shown in
Table 1. The sample size ranged from 10–119. One
study had included only women [27]. Most studies used
oral cholecalciferol as supplemental vitamin D. The dose
of cholecalciferol ranged from 400 IU to 5600 daily or
60, 000 IU weekly. Calcitriol, the active form of vitamin
D was used in three studies [18,37]. Vitamin D2 was
used in one study [33]. A single dose intramuscular in-
jection of vitamin D3 was used in three studies
[21,28,29]. None of the studies had used doxercalciferol
or alphacalcidol.
Fourteen studies had assessed change in HbA1c over
time after vitamin D supplementation. The study that
had used calcitriol had the largest sample size (n = 119)
and the results suggested a significant improvement in
mean HBa1c after eight weeks from 8.4 to 7.1 [18]. Con-
versely the second study that had used calcitriol, found a
Table 1 Clinical and biochemical characteristics of the short-term studies**
Author, year, country Study design, N Duration Intervention Age (years) Change in
HbA1c and HOMA
Comments
Parekh [28], 2010, India RCT, N = 28 4 weeks 300000 IU
vitamin D IM
No data HbA1c 7.58 ± 0.57 vs.
7.67 ± 0.61, p=.393.
No difference in HOMA-IR
No improvement in
HbA1c and HOMA-IR
Borissova [27], 2003, Bulgaria Longitudinal study,
N = 10
1 month Vitamin D3
1332 IU daily
No data No data on HbA1c.
Decrease of 21% in
HOMA-IR but not significant
Insulin secretion and
resistance improved
Sugden [33], 2008, UK RCT, N = 87 8 weeks 100 000 IU
vitamin D2
65 ± 10 HbA1c Change: 0.01 ± 0.60,
p=.74. Change in HOMA-IS:
−39.7 ± 79.3, p=.72
HOMA-IS improved
in those with a
25-OHvitamin
D increase of ≥11
nmol/l. No change in
HbA1c
Witham [29], 2010, UK* RCT, N = 61 8 weeks Vitamin D3
100,000/200,000
IU single dose
65 ± 11 HbA1c 7.0 (1.6) vs. 7.1
(2.0 HOMA-IR 11.7
(12.7) vs. 13.5 (12.8)
HOMA-IR and HbA1c did
not improve with either
dose of vitamin D3
Talaei [19], 2013, Iran Longitudinal study,
N = 100
8 weeks 50,000 U vitamin
D3 orally/week
54 + 11 No data on HbA1c




Sabherwal [35], 2010, UK Retrospective study,
N = 52
3 months 400 IU vitamin D3 59 ± 8 HbA1c 8.9 ± 0.9%
vs. 8.5 ± 0.8%, p <0.001
No data on
HOMA parameters
HbA1c improved in both
the vitamin D deficient
and insufficient groups
Nikooyeh [22], 2011, Iran RCT, N = 90 12 weeks 500 IU vitamin
twice daily
51 ± 6 HbA1c −0.4 ± 1.2%
(p < 0.001)
Significant improvement
in HbA1c and HOMA-IR
HOMA-IR 3.3 ± 1.8
vs. 2.7 ± 1.5
Shab-bidar [23], 2011, Iran RCT, N = 100 12 weeks 1,000 IU vitamin
D3 daily
52.5 ± 7.4 HbA1c 8.7 ± 1.8 vs.
7.8 ± 1.3, p = 0.001
QUICKI: 0.29 ± 0.02





Yiu [31], 2013, Hong Kong RCT, N = 100 12 weeks 5000 IU vit. D3 daily 65 ± 8 HbA1c 7.35 vs. 7.20,




Bonakdaran [18], 2012, Saudi Longitudinal
study, N = 119
8 weeks 0.5 μg calcitriol daily 55 ± 11 HbA1c 8.4 + 1.8
vs. 7.1 ± 1.6, p = 0.01.
No data on HOMA
parameters
HbA1c improved
Heshmat [21], 2012, Iran RCT, N = 42 3 months Single IM 300,000
IU vitamin D3
56 ± 9 Percentage change




















Table 1 Clinical and biochemical characteristics of the short-term studies** (Continued)
Eftekhari [37], 2011, Iran RCT, N = 70 12 weeks Calcitriol 0.25 μg daily 54 ± 9 HbA1c 7.1 ± 1.6
vs. 7.9 ± 2.1, p=.004
Attenuated the increase
in glycaemia, and increased
HOMA-B, but no effect on IR
HOMA-IR 3.6 ± 2.5
vs. 4.8 ± 2.7
HOMA-B 3.4 ± 3.0
vs. 4.8 ± 3.8, p < 0.005
Kota [36], 2011, India RCT, n = 30 12 weeks Oral cholecalciferol
60,000 units/week
38.4 ± 19.6 HbA1c 11.1 ± 1.3
to 7.7 ± 0.9 versus
10.3 ± 1.2 to 7.8 ± 1.1
(p > 0.1) in placebo.
No data on HOMA
parameters
HbA1c did not show
significant improvement1
Soric [30], 2012, USA RCT, N = 19 12 weeks 2000 IU vitamin D3 daily 54 ± 9 Change in A1c
0.4 ± 1.2, p = 0.16
Significant reduction
in only in those with
HbA1c >9.0%
No data on HOMA
parameters
Kampmann [40], 2014, Denmark RCT, n = 8 in each group 12 weeks Cholecal ciferol2 62 ± 4. ΔHbA1c 0.0004 ± 0.002,









Tabesh [39], 2014, Iran RCT, N = 70 8 weeks Cholecalciferol divided
into 4 groups***
50.2 ± 6.6 HbA1c [−0.70 ± 0.19%
(−8.0 ± 0.4 mmol/mol)
p = 0.02] change from baseline.







IM: Intramuscular, RCT: Randomized controlled trial. *This study has provided data on both short term and long term changes in glycemic parameters.
**Studies with a follow up of ≤ 3 months were considered as short-term studies.
***(1) 50,000 U/week vitamin D + calcium placebo; (2) 1,000 mg/day calcium + vitamin D placebo (3) 50,000 U/week vitamin D + 1,000 mg/day calcium or (4) vitamin D placebo + calcium placebo.
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in this RCT (n = 35 in each group). However, authors
noted that the use of calcitriol was associated with im-
provements in insulin secretion [37]. Of the remaining
studies that had used cholecalciferol and assessed change
in HbA1c over time, five studies found significant im-
provement in HbA1C at three months [22,23,30,35,39]. In
the RCT conducted by Soric et al., patients with higher
baseline HbA1c had a significantly greater reduction in
HbA1C after 12 weeks [30]. Similarly, in the RCT con-
ducted by Sugden et al., HOMA parameters significantly
improved though HbA1c remained constant [33]. How-
ever, in the RCT that used a single intramuscular injection
of vitamin D, HbA1c and HOMA-IR remained stable des-
pite correction of low vitamin D status [21]. Similar lack
of improvement in HbA1c and HOMA-IR were noted in
the RCT conducted by Witham and colleagues. In this
study, a large single dose of vitamin D3 was used [29]. Of
particular note, one study that used hyperinsulinemic
euglycemic clamp technique found that insulin sensitivity
and HbA1c did not improve significantly [40]. In sum-
mary, ten short-term studies found improvement in
HbA1c, HOMA-B and HOMA-IR though only four stud-
ies had analyzed all three outcomes [19,22,37]. QUICKI,
an index of insulin sensitivity was shown to improve at
12 weeks in another RCT [23,39]. Certain parameters such
as glycemic control and serum vitamin D levels may
have affected the response in glycemic parameters. For
instance, in one RCT, HbA1c improvement was noted
only in subjects who had a baseline HbA1c greater than
9% [30]. Similarly, in the RCT conducted by Sugden
et al., HOMA parameters significantly improved in
patients who had a 25-OHvitamin D increase of
11 nmol/l or more [33].
Clinical and biochemical characteristics of the long-term
studies
There were nine studies identified as long-term studies.
Six of them were RCTs. Data are shown in Table 2. Vari-
ous studies had a sample size ranging from 22–204 and
the duration of follow-up ranged from four to eighteen
months. Eight studies had assessed the change in HbA1c
over time after vitamin D supplementation. Most studies
used oral cholecalciferol for supplementation. The dose of
cholecalciferol ranged from 400–5700 IU daily to 40,
000 IU monthly. Calcitriol and vitamin D2 were not used
in any of the long-term studies. A single dose intramuscu-
lar injection of vitamin D3 was used in two studies
[29,38]. Only three studies had a follow up period beyond
six months.
Contrary to the results of the short-term studies, fewer
long-term studies observed improvement in HbA1c
[16,20,38]. Two studies that had a 4-month follow-up
did not find any improvement in HOMA parameters orHbA1c [29,34]. Among the four studies with a follow up
of six months, one study that used a higher supplemen-
tary dose of 40,000 IU per week observed that glycaemic
control did not improve in subjects with normal serum
25-hydroxyvitamin D levels [32]. Conversely, another
study that used a single high dose of intramuscular
vitamin D, reported significant improvements in
HOMA-IR after six months [38]. The study from
Saudi Arabia had the longest follow up of 18 months
and noted that HOMA-B improved over that period
[20]. The beneficial effect was more pronounced in
women than men. Interestingly the serum vitamin D
levels were in the suboptimal range despite all subjects
taking 2000 IU vitamin D daily [20]. HOMA parame-
ters showed improvement only in two studies [20,38].
However HOMA measures remained stable in the
remaining five studies in which this was assessed
[15,17,29,32,34].
Quality assessment
According to the Jadad scale, seven RCTs (11/17) in-
cluded in this systematic review were of relatively high
quality (Jadad score ≥3) and details are shown in Table 3.
The quality assessment of the longitudinal cohort studies
is presented in Table 4.
Discussion
This systematic review summarizes the most recent ad-
vances in our knowledge of evidence on how vitamin D
supplementation affects glycemic parameters in patients
with type 2 diabetes. There have not been many system-
atic reviews or meta-analyses on this topic [14,42,43].
Past narrative reviews have primarily focused on data
obtained from preventive trials and observational studies
[44]. We found 24 eligible studies out of which 17 were
RCTs. Results of the various short-term studies included
in this systematic review suggested that vitamin D sup-
plementation had a positive impact on glycemic control
and metabolic parameters such as insulin resistance and
beta cell dysfunction. However, the evidence is weak due
to the low methodological quality of the studies. Further,
we found that there was no significant effect on HbA1c,
beta cell function and insulin resistance based on the
results of the long term studies that had an intervention
period beyond three months. Only three long-term stud-
ies demonstrated a favorable profile but two of them
were of inferior quality when compared to the remaining
RCTs that demonstrated a lack of significant effect on
glycemic parameters [16,20]. We also observed a lot of
heterogeneity in the methodology of the studies (short
term trials versus long term studies), inclusion criteria,
supplementation of vitamin D (oral dose versus. intra-
muscular, ergocalciferol versus calcitriol or cholecalcif-
erol) and the duration of follow up. Clearly there is a





Duration Intervention Age (Years) Change in HbA1c
and HOMA
comments
Witham [29] 2010, UK* RCT, N = 61 16 Weeks Vitamin D3 100,000 or
200,000 IU single dose
65 ± 11 HbA1c 7.0 ± 1.6 vs. 6.9 ± 1.5 HOMA-IR and
HbA1c did
not improveHOMA-IR11.7 ± 12.7 vs. 15.9 ± 14.3
Patel [34], 2010, USA RCT, N = 24 4 Months Vitamin D3 400 or 1200 IU 58 ± 3 HbA1c 6.7 ± 0.3 vs. 6.9 ± 0.2 QUICKI & HbA1c
did not improve
QUICKI 0.35 ± 0.01 vs. 0.35 ± 0.011
Jorde [32], 2009, Norway RCT, N = 32 6 Months Vitamin D3 (40,000 IU/week) 58 ± 10 HbA1c 8.0 ± 1.3 at baseline and
changed by −0.2 ± 0.9 (p=.90 vs.




HOMA-IR 27.6 ± 34.3 at baseline
and changed by 0.3 ± 23.5
(p=.58 vs. change in placebo group)
Jehle [38], 2014, Switzerland RCT, N = 55 6 Months 300,000 IM 67 ± 3 Significant intergroup difference in
the ΔHbA1c (relative change +
2.9 ± 1.5% in the vitamin D group
vs. +6.9 ± 2.1% in placebo group.
HOMA-IR decreased
by 13 ± 6% in the vitamin D group
and increased by 10 ± 5% in the
placebo group (p = 0.032)
Improved HOMA-IR
and HbA1c
Strobel [15], 2014, Germany RCT, N = 86 6 Months Vigantol oil once a week
(1904 IU)
61 (36–78) Groups: 25 (OH) vitamin




HbA1c 50 vs. 54 mmol/mol
Hb, p = NS
Huang [11], 2012, China Longitudinal,
N = 22
6 Months Vitamin D3 800 IU/d 61 ± 10 HbA1c 7.1 ± 1.4 vs.
7.2 ± 1.4, p = 0.86
HbA1c remained
stable
No data on HOMA parameters
Alam [16], 2014, UK Retrospective
audit, N = 204
8.0 ± 4.0 months Vitamin D2 or vitamin D3*** 61 ± 12 HbA1c 8.5 ± 1.7 vs. 8.0 ± 1.5






No data on HOMA parameters





HOMA-IR 4.2 vs. 6.1, p=.243,
HOMA-B 84.7 vs. 42.5, p = 0.184
Al-Daghri [20], 2012, Saudi Prospective
longitudinal,
N = 92
18 months Vitamin D3 2000 IU 54 ± 10 No data on HbA1c HOMA-B showed
improvement until
18 monthsHOMA-B: 52 ± 9 vs. 97 ± 15,
p = 0.002
IM: Intramuscular, RCT: Randomized controlled trial. *This study has provided data on both short term and long term changes in glycemic parameters.
**Studies with a follow up of > 3 months were considered as long-term studies.
1QUICKI: An index of insulin sensitivity.


















Table 3 Quality assessment of eligible randomized controlled studies as assessed by the Jadad scale
Was the study described
asrandomized?


















Parekh [28] 1 1 1 0 1 4
Sugden [33] 1 1 1 0 1 4
Witham** [29] 1 1 1 1 1 5
Eftekhari [37] 1 0 1 0 0 2
Soric [30] 1 0 0 0 0 1
Heshmat [21] 1 0 1 0 0 2
Yiu [31] 1 1 1 1 1 5
Nikooyeh [22] 1 0 1 0 1 3
Shab-bidar [23] 1 0 1 0 0 2
Kota [36] 1 0 1 0 0 2
Tabesh [39] 1 1 1 ’1 1 5
Kampmann [40] 1 1 1 1 0 4
Long term studies*
Witham** [29] 1 1 1 1 1 5
Patel [34] 1 0 0 0 1 2
Jorde [32] 1 0 0 0 1 2
Jehle [38] 1 1 1 1 0 4
Strobel [15] 1 0 1 1 0 3
Breslavsky [17] 1 0 1 0 1 3
*Studies with a follow up of ≤ 3 months were considered as short-term studies. Studies with a follow up of > 3 months were considered as long-term studies.
**This study has provided data on both short term and long term changes in glycemic parameters.
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term follow up to assess the potential beneficial effect of
vitamin D supplementation in glycemic control, beta cell
function and insulin resistance.
Our systematic review updates the findings of the pre-
vious meta-analyses. Our conclusions are similar to that
of a recent meta-analysis [39]. But our review is more
selective and detailed since we had focused specifically
on intervention studies in patients with type 2 diabetes
[39]. The meta-analysis by Seida et al. was different from
our review in many ways [42]. Their meta-analysis may
have missed out on some important studies due to the
exclusion of non-RCT longitudinal studies [16,18-20,35].
They had also excluded studies in which synthetic vita-
min D preparations or vitamin D2 were used. All the
RCTs involved in this meta-analysis had sample sizes
less than 50. In addition, some trials included in this
meta-analysis had not studied vitamin D related gly-
cemic outcomes as their primary analysis [23,36]. Our
systematic review included 24 studies including 17 RCTs
where as the meta-analysis by Seida et al. assessed data
from 15 RCTs and the sample size for the pooled analysiswas much smaller [42]. Nevertheless our conclusions are
similar and further strengthen their conclusions that vita-
minD3 supplementation might not decrease insulin resist-
ance and hyperglycemia in patients with established type 2
diabetes. Similarly, another recent meta-analysis published
in 2012 concluded that there was insufficient evidence to
support a beneficial role of vitamin D on hyperglycaemia
or insulin resistance [14]. However, this meta-analysis was
conducted by pooling data from patients with normal glu-
cose tolerance, impaired glucose tolerance and type 2
diabetes [29,33,45-47]. Also the literature search was re-
stricted to March 2011 and hence they could only capture
very limited number of studies. Many RCTs have been
conducted since then and hence our systematic review
contains more recent information. In a meta-analysis
involving 328 patients and 6 RCTs, vitamin D supplemen-
tation was shown to improve HbA1c but failed to show
any improvement in other parameters such as fasting
blood glucose, quantitative insulin sensitivity check index
(QUICKI), HOMA-B, and HOMA-IR [43].
Several possible explanations exist for the lack of
beneficial effect of vitamin D on metabolic outcomes
Table 4 Quality assessment of eligible longitudinal cohort studies as assessed by the Newcastle–Ottawa quality
assessment scale
Short-term studies** Long term-studies**
Selection Sabherwal [35] Borissova [27] Talaei [19] Bonakdaran [18] Alam [16] Huang [11] Al-Daghri [20]
Representativeness of the
exposed cohort
* * * * * * *
Selection of the non- exposed cohort * *
Ascertainment of exposure * * * * * * *
Demonstration that outcome
was not present at start of study
* * * * * * *
Comparability
Comparability of cohorts *
Outcome
Assessment of outcome * * * * * * *
Was follow-up long enough * * * * * * *
Adequacy of follow up of cohorts * * * * * * *
A study can be awarded a maximum of one star for each numbered item within the selection and outcome categories. A maximum of two stars can be given
for comparability.
**Studies with a follow up of ≤ 3 months were considered as short-term studies. Studies with a follow up of > 3 months were considered as long-term studies.
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betes may be attributed. First factor linked to vitamin D
is related to its dosing. Sub optimal dosing of vitamin D
may be one potential reason as not all studies docu-
mented correction of low vitamin D and high PTH.
Some studies in the past have reported that the positive
effect of vitamin D on beta-cell function and glucose
tolerance is partly be due to correction of hypocalcaemia
and secondary hyperparathyroidism [48]. The dose of
vitamin D used may not have been adequate; most stud-
ies used daily doses of less than 2000 IU and daily doses
up to 5000 IU may be essential to raise serum 25 (OH)
vitamin D levels above the 75-nmol/L level. The appro-
priate dose of vitamin D that can achieve non-skeletal
benefits still remains unclear. As observed in some stud-
ies, supraphysiological dosing of vitamin D may have
been harmful [32]. Third, there could be differences
between vitamin D2 and D3. For example, one study in
this review observed that favorable change in HbA1c oc-
curred only in patients treated with ergocalciferol during
the initial course of the study [16]. Forth, baseline vita-
min D status is a potential confounder on glycemic sta-
tus and not many studies analyzed the effect of vitamin
D supplementation on patients with vitamin D defi-
ciency at baseline. Fifth, genetic factors related to vita-
min D metabolism might play a role. It is likely that
some ethnic groups might have a lower sensitivity to the
effects of vitamin D and PTH. Individual variability may
also be partly explained by vitamin D receptor polymor-
phisms. Moreover, the lack of significant association
might have occurred due to the fact that the studies
might have been underpowered with small sample size,
short duration of intervention, lack of appropriatecontrol groups and post hoc heterogeneity in the type
and dose of formulations of vitamin D. Diabetes related
reasons likely responsible for not finding a beneficial ef-
fect with vitamin D treatment include degree of hyper-
glycemia and duration of diabetes. Selective inclusion of
patients with higher baseline glucose or HbA1c values
may have been associated with greater improvements
with vitamin D supplementation. In addition, the in-
cluded subjects in some studies were treated with met-
formin and/or insulin, which might have masked the
positive effects of vitamin D [23,32]. Next, only one
study had used the gold-standard method of hypergly-
cemic clamp (for insulin secretion or sensitivity), but no
significant association was noted [40].
The strengths and limitations of this systematic review
need mention. Although we performed a comprehensive
search of electronic literature some studies could exist
that have not been included. Other limitations of our
study are based on the quality and methodological flaws
of the included studies as well as the lack of availability
of sufficient information from eligible studies. First, de-
tailed information about confounding factors such as
ethnicity, physical activity, baseline HbA1c, body mass
index, obesity, sun exposure, seasonal changes in vitamin
D, dietary vitamin D intake, calcium intake, vitamin D
receptor polymorphisms, baseline vitamin D status, and
compliance with vitamin D supplements that could in-
fluence the response of vitamin D was not available in
all of the included studies [49]. Data was also lacking
regarding the compliance with supplements and possible
gender differences in metabolic effects. Second, almost
all studies assessed insulin secretion and resistance
based on HOMA related parameters that are not as
Nigil Haroon et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:3 Page 10 of 11accurate as the glucose clamp techniques. It can be ar-
gued that clamp techniques are invasive to be conducted
in large-scale studies. But there are more reliable dy-
namic tests now being used to assess insulin sensitivity
and beta cell function. Furthermore, most trials concen-
trated only on short-term or intermediate effects, such
as glycemic status and insulin resistance. Long-term tri-
als investigating the occurrence of micro and macrovas-
cular complications were seldom conducted and such
trials may bring in a new dimension to the field. Some
studies failed to meet the endpoints for improved insulin
sensitivity and beta cell function though confirmed im-
provement in HbA1c [23,37]. Lack of statistical analysis
limits our ability to make a single conclusion from differ-
ent studies. Finally, the included studies were conducted
mostly in Caucasians making the results less generalizable
to other racial groups. Our systematic review has several
strengths. This review is based on an up to date literature
search represents the most extensive review on this topic
so far. The eligible studies were either RCTs or longitu-
dinal studies. Most studies had prospective designs, adding
more strength to our results. The data were extracted
from well-reviewed studies using a comprehensive litera-
ture search. We relied on duplicate independent judgment
and there was sufficient inter-observer agreement. The
extensive review shows that the evidence is not of good
quality, mainly because of the many methodological limi-
tations of the included studies. Our systematic review
underscores the need for future studies given that both
vitamin D deficiency and diabetes are conditions with
huge public health concern worldwide.
Conclusions
Based on our critical review, we conclude that currently
available evidence based on randomized controlled trials
and longitudinal studies suggest that vitamin D supple-
mentation might not improve hyperglycemia, beta cell
secretion or insulin sensitivity in patients with estab-
lished type 2 diabetes. This shows that the pathogenetic
and therapeutic role of vitamin D in glucose metabolism
is still unclear. Experimental studies as well as large scale
RCTs with good study design, optimal vitamin D supple-
mentation and long-term follow up are needed on this
topic.
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